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Background: Dialysis disequilibrium syndrome is characterized by neurological symptoms resulting from cerebral
edema, which occurs as a consequence of hemodialysis. Dialysis disequilibrium syndrome most often occurs in
patients who have just started hemodialysis, during hemodialysis, or soon after hemodialysis; although it may also
occur in patients who are under maintenance hemodialysis with pre-existing neurological disease.
Case presentation: A 70-year-old woman, who had been receiving maintenance hemodialysis for one year, was
diagnosed with ovarian cancer by ascites cytological examination. Two years later, she reported severe headache
and nausea during hemodialysis and was diagnosed with dialysis disequilibrium syndrome. Although brain images
revealed mild hydrocephalus without any mass lesions, poorly differentiated adenocarcinoma cells were detected in
her cerebrospinal fluid. These findings indicated that DDS was induced by neoplastic meningitis due to ovarian
cancer metastasis.
Conclusion: Neoplastic meningitis should be considered and excluded in hemodialysis patients with dialysis
disequilibrium syndrome and malignancy by cytological examination of the cerebrospinal fluid even if cerebral
imaging shows no obvious lesions. This is the first reported case of dialysis disequilibrium syndrome induced by
neoplastic meningitis in a patient receiving maintenance hemodialysis.
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Dialysis disequilibrium syndrome (DDS), first described by
Kennedy et al. in 1962 [1], is characterized by neurological
symptoms resulting from cerebral edema, which occurs as
a consequence of hemodialysis [2]. DDS most often occurs
in patients who have just started hemodialysis, during
hemodialysis, or soon after hemodialysis; although it
may also occur in patients who are under maintenance
hemodialysis with pre-existing neurological disease [3-5].
Neoplastic meningitis (NM) is caused by dissemination
of malignant cells to the leptomeninges and subarachnoid
space. NM occurs in 4-15% of all patients with solid tumors
and presents with variable neurological manifestations. NM
deriving from tumors that were previously rarely associated* Correspondence: niino@med.niigata-u.ac.jp
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stated.with NM, such as prostate cancer, ovarian cancer, gastric
cancer, cervical cancer, and endometrial cancer, appear
to be increasing [6].
Aggressive treatment including surgical resection, ir-
radiation, local intrathecal or systemic chemotherapy
is not improved patient’s survival. The median survival
time for patients with NM is within the range of 2-6
months [7].
Here, we report a case of DDS induced by NM in a
patient receiving maintenance hemodialysis.
Case presentation
A 72-year-old woman was admitted to hospital reporting
dizziness and gait disturbance. She had been under
maintenance hemodialysis for three years because of
advanced diabetic nephropathy. At 70 years of age, she was
diagnosed with stage IIIc ovarian cancer with carcinomat-
ous peritonitis. Poorly differentiated adenocarcinoma cells
were detected in the ascites. She received a simple totalal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Figure 1 Cranial computed tomography images (A) one month before admission, (B) on admission, and (C) three weeks after admission.
No mass lesions were present. However, mild hydrocephalus exacerbation with disappearing sulcus and ventricular distention were observed.
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of chemotherapy with paclitaxel and carboplatin, followed
by an additional six cycles of chemotherapy.
When she admitted to hospital, her blood pressure was
113/54 mmHg, and body temperature was 36.6°C. She
was conscious and a physical examination of the nervous
system revealed only positive Babinski reflex sign without
any other neurologic abnormality including nystagmus.
We could not evaluate her gait disturbance because her
II-IV metatarsal bone was fractured during a fall that
occurred several days before admission. In addition to the
chief complaints, transient hypertension, headache, and
nausea appeared during each hemodialysis session. Her
symptoms appeared about one hour after the beginning of
hemodialysis, and moreover, they lasted during treatment,
and subsided gradually after the session. Thus, a diagnosis
of DDS was made.
Findings from laboratory examinations were as follows;
hemoglobin, 11.7 g/dL; hematocrit 35.9%; white blood
cells (WBCs), 3,990 WBC/μL; sodium, 141 mmol/L;
potassium 4.9 mmol/L; chloride, 101 mmol/L; blood urea
nitrogen, 56.3 mg/dL; creatinine, 6.24 mg/dL; C-reactiveFigure 2 Photomicrographs of cancer cells. Cancer cells covering the su
magnification x40) thoracic spinal cord (hematoxylin and eosin stain). (C) C
viscous liquid in their endoplasmic reticulum (hematoxylin and eosin stain,protein, 0.18 mg/dL; B-type natriuretic peptide, 276.38
pg/mL; blood glucose, 137 mg/dL; hemoglobin A1c,
6.7%; and normal liver function tests.
Both contrast-enhanced cranial computed tomography
and non-enhancement cranial magnetic resonance imaging
did not demonstrate any intracranial pathological abnor-
malities including mass lesions, bleeding, and metastatic
disease. Five days after the admission, she presented with
consciousness disturbance and short-term memory loss,
which gradually worsened especially during hemodialysis.
Cranial computed tomography images showed mild exacer-
bation of hydrocephalus (Figure 1). Intracranial pressure at
that time was 180 cmH2O (normal intracranial pressure: 60
to 150 cmH2O), and poorly differentiated adenocarcinoma
cells, which were compatible with the metastasis of ovarian
cancer cells, were detected in cerebrospinal fluid (CSF).
NM had a negative effect on the patient’s general health.
She died 42 days after admission.
Postmortem pathological examinations revealed cancer
cells covering the surface of the brain and spinal cord
(Figure 2); however, no other apparent metastatic lesions
were detected.rface of (A; original magnification x100) cerebrum and (B; original
ancer cells were poorly differentiated adenocarcinoma cells with
original magnification x200).
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We believe this the first reported case of DDS induced
by NM in a patient on maintenance hemodialysis. DDS
is characterized by neurological symptoms including
headache, nausea, emesis, blurred vision, muscular twitch-
ing, disorientation, hypertension, tremors, and seizures at-
tributed to cerebral edema that appears during or within 24
hours after hemodialysis. Cerebral edema is presumably
caused by the significant urea gradient between blood and
brain after hemodialysis, resulting in an inflow of water into
the brain [1,8].
Trinh-Trang-Tan et al. have demonstrated that the
molecular basis for the development of cerebral edema,
may be a reduced expression of the urea transporter and
increased expression of aquaporin in the brain, as was
observed in uremic rats [9]. However, the precise patho-
genesis of DDS remains unclear [2].
DDS mostly occurs in patients who have just started
hemodialysis. However, it has been reported that intracra-
nial bleeding, traumatic brain injury, and/or meningioma
can cause DDS even in patients undergoing maintenance
hemodialysis [3-5].
NM is caused by dissemination of malignant cells to the
leptomeninges and subarachnoid space. The presence of
malignant cells in the CSF establish an accurate diagnosis
of NM. NM presents with variable neurological manifesta-
tions such as headache, altered mental state, nausea, and
vomiting [6,10,11]. In the present case, DDS, but not NM
itself, was thought to be responsible for the symptoms, be-
cause her neurological abnormalities were observed only
during hemodialysis. Walters et al. have demonstrated that
regular dialysis treatment causes considerable increases in
cerebral edema without significant neurological symptoms
[12]. In this case, DDS might result from cerebral edema
caused by the additive effects of both hemodialysis and NM.
Imaging techniques may not be suitable for detecting
NM in patients on hemodialysis. Magnetic resonance im-
aging with gadolinium enhancement is useful for detecting
NM [6,13]. According to the recent guidelines on nephro-
genic systemic fibrosis (NSF) and gadolinium-based con-
trast media, contrast agents with intermediate risk of NSF
(Gadobenate dimeglumine, Gadofasvest trisodium, Gadoxe-
tate disodium) and contrast agents with the lowest risk of
NSF (Gadobutrol, Gadoterate meglumine and Gadoteriol)
should be used with caution in patients with CKD4 and 5,
including patients on dialysis, with at least 7 days between
2 injections [14]. Taken together, gadolinium-enhanced
MRI may be elective modalities for diagnosis of NM in
patients on dialysis. However, aggressive removal of
gadolinium by hemodialysis did not have the evidence
to prevent developing NSF [15]. Thus, we should keep
in mind that exposure of gadolinium-based contrast agents
is a significant risk factor for NSF in patients with kid-
ney disorders [15-17]. Further, contrast-enhanced cranialcomputed tomography does not have the required sen-
sitivity to detect NM [13]. Therefore, when hemodialysis
patient is suspected to have NM, cytological analysis of
the CSF is required.
Patients who receive hemodialysis for end-stage renal
disease are at an increased risk of developing cancer and
this risk increases with age [18]. In addition, NM has
become increasingly common, partly because of the
prolonged survival of patients with metastatic disease
[6]. Thus, it is recommended that physicians consider NM
as a possible cause for DDS in patients on maintenance
hemodialysis with malignancy.
In conclusion, this is the first reported case of DDS in-
duced by NM. For patients on maintenance hemodialysis
with cancer who present with DDS, NM should be con-
sidered and excluded by cytological examination of the
CSF even if cerebral imaging shows no obvious lesions.
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